As tools become more precise and non-invasive, doctors are able to diagnose and treat heart conditions with greater accuracy and efficiency.

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter and full-year ended Dec. 31, 2024.

CoreMedic announced that it picked up new funding in a Series B extension to support its transcatheter mitral valve repair ...

With new transcatheter options for the repair or replacement of tricuspid valves, the role and timing of repair — whether surgical or minimally invasive — is entering a time of transition.

The Heart Valve Devices Market is driven by advancements in aortic, mitral, tricuspid, and pulmonary valve technologies. It ...

Q. I have a leaky heart valve that may need surgery down the road. Can you tell me about heart-valve surgery in one of your columns? A. First, let’s explain briefly how the heart works.

Navi Mumbai: A 78-year-old patient with severe mitral regurgitation has successfully undergone the MitraClip procedure, marking a significant advancement in minimally invasive heart care. The rare and ...

Beyond surgical excellence, St. Elizabeth prioritizes a highly specialized and patient-focused approach to cardiac care.

Sarah Joseph, 88, had no energy and could barely walk the length of her living room. Diagnosed with a faulty heart valve, ...

We came across a bullish thesis on Edwards Lifesciences Corporation (EW) on Substack by Natan. In this article, we will summarize the bulls’ thesis on EW. Edwards Lifesciences Corporation (EW)’s share ...

Background Mitral valve repair (MVr) is the gold standard treatment for degenerative mitral regurgitation, yet there is ...

When going through open-heart surgery, patients like Williams are often so concerned about the operation itself that they may not consider what recovery will be like. “Many of o ...